Last reviewed · How we verify
Valacyclovir celecoxib dose 1 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Valacyclovir celecoxib dose 1 (Valacyclovir celecoxib dose 1) — Bateman Horne Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Valacyclovir celecoxib dose 1 TARGET | Valacyclovir celecoxib dose 1 | Bateman Horne Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Valacyclovir celecoxib dose 1 CI watch — RSS
- Valacyclovir celecoxib dose 1 CI watch — Atom
- Valacyclovir celecoxib dose 1 CI watch — JSON
- Valacyclovir celecoxib dose 1 alone — RSS
Cite this brief
Drug Landscape (2026). Valacyclovir celecoxib dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/valacyclovir-celecoxib-dose-1. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing